person · Reporting owner
Chapman Christopher C JR
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC.MIRA · Entity 7362 | Director · Executive Chairman | August 17, 2023 | August 21, 2023 |
| Q/C TECHNOLOGIES, INC.MYMD · Entity 7735 | Director · President, Chief Med. Officer | June 07, 2023 | June 09, 2023 |
| Telomir Pharmaceuticals, Inc.TELO · Entity 6962 | Director · CEO & Chairman | February 08, 2024 | February 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MIRA PHARMACEUTICALS, INC.
Report date August 17, 2023 · Filed August 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2033-08-17 | Direct | 50,000 |
Reported balance
After 2023-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-17 · Grant · Acquired 50,000 · Balance 50,000 F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 17, 2023. F2: The stock options were issued to the Reporting Person on August 17,2023, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated. The award vested in full on August 17,2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 17, 2023.
F2: The stock options were issued to the Reporting Person on August 17,2023, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated. The award vested in full on August 17,2023.
Q/C TECHNOLOGIES, INC.
Report date June 07, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.66 · Expires 2028-06-07 | Direct | 300,000 |
Reported balance
After 2023-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-07 · Grant · Acquired 300,000 · Balance 300,000 F1: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.
Telomir Pharmaceuticals, Inc.
Report date February 08, 2024 · Filed February 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 975,610 |
Reported balance
Holding disclosure · report date 2024-02-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 975,610 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2023 Filed Aug 21, 2023 18:00 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001493152-23-029733 · ownership.xml · derivative · entry 1 Chapman Christopher C JR · CIK 0001340428 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-08-17 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 17, 2023. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on August 17,2023, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated. The award vested in full on August 17,2023. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 22:00 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001493152-23-020795 · ownership.xml · derivative · entry 1 Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-06-07 F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date. Read SEC document |
| April 04, 2023 Filed Apr 5, 2023 20:28 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantEmployee Stock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001493152-23-011040 · ownership.xml · derivative · entry 1 Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2028-04-04 F1 · derivative.exercise_date: The stock options vest as follows: (i) 250,000 on the date of grant; (ii) 250,000 on the first anniversary of the date of grant; and (iii) 250,000 on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 21:20 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantRestricted Stock Units · Derivative | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-025601 · ownership.xml · derivative · entry 1 Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company"). F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control. F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 20:53 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantStock Option (Right to Buy) · Derivative | 96,475 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001493152-21-009385 · ownership.xml · derivative · entry 5 Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,475 Underlying: Common Stock · 96,475 shares Expires 2023-04-16 F6 · price: Received in the Merger in exchange for a stock option to acquire 250,000 shares of common stock of the Former Entity at $1.00 per share. F3 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 20:53 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantStock Option (Right to Buy) · Derivative | 77,180 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001493152-21-009385 · ownership.xml · derivative · entry 4 Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,180 Underlying: Common Stock · 77,180 shares Expires 2023-04-16 F5 · price: Received in the Merger in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share. F3 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 20:53 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantStock Option (Right to Buy) · Derivative | 77,180 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001493152-21-009385 · ownership.xml · derivative · entry 3 Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,180 Underlying: Common Stock · 77,180 shares Expires 2023-04-16 F4 · price: Received in the Merger in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share. F3 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 20:53 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantStock Option (Right to Buy) · Derivative | 38,590 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001493152-21-009385 · ownership.xml · derivative · entry 2 Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,590 Underlying: Common Stock · 38,590 shares Expires 2023-04-16 F2 · price: Received in the Merger in exchange for a stock option to acquire 100,000 shares of common stock of the Former Entity at $1.00 per share. F3 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 20:53 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantCommon Stock | 96,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-009385 · ownership.xml · nonDerivative · entry 1 Chapman Christopher C JR · CIK 0001340428 · Director · President, Chief Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,475 F1 · price: Received in exchange for 250,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.